Weight Loss Competitors: How Do They Compare To Levity?

When deciding to try medicated weight loss, it’s important you get your treatment from a licensed provider who can meet your needs and help you reach your goals. The popularity of weight loss injectables means there are now many providers to choose from, but how do they compare to Levity? In this post, we compare Levity to some of our competitors so you can make an informed decision about where to start your weight loss journey. 

Levity vs Ivim Health 

Ivim Health, like Levity, offers a variety of branded and compounded medications, including: Wegovy, Ozempic, Mounjaro and Compounded Semaglutide. You can access branded GLP-1s through your insurance provider, if you qualify — you’ll receive free initial benefits verification, then you pay a $74.99/month membership fee and your co-payment. For Ivim’s compounded medications, your treatment starts at $199.99/month, which covers your membership, medication and health coaching. Your monthly payment increases as your dosage increases. 

With Levity, there are no membership fees or long-term contracts. Evidence-based healthcare, expert health coaching, express delivery and clinical support come, as standard, with all of our plans. You pay $175 for your first month of Compounded Semaglutide, then a flat $225/month for the remainder of your treatment plan — regardless of dosage increases. 

Levity vs Mochi Health

Mochi offers a variety of weight loss medications, from GLP-1s like Wegovy, Ozempic and Mounjaro to other weight loss aids like Alli and Contrave. You can also get Compounded Semaglutide ($99/month, all doses) and Compounded Tirzepatide ($275/month, all doses) from Mochi’s partner compounding pharmacies.

However, unlike Levity, you have to pay a $79/month membership fee on top of your medication. With Mochi, your medication is supplied by local pharmacies, who control the process of creating your treatments. Levity, however, compounds and dispatches your treatment in-house, so we can oversee the whole process. 

Levity vs Hers

Hers offers a variety of semaglutide-based injectable treatments, including Wegovy, Ozempic and Compounded Semaglutide. A Compounded Semaglutide plan starts at $199/month, however you must pay for the whole 12-month plan upfront before commencing treatment. This price also may increase depending on the product and plan you choose. 

At Levity, we understand that medicated weight loss isn’t just an investment in your health, but a financial one too. That’s why you only pay for your current dose, not future doses. Every four weeks — when it’s time for you to titrate your dose up — you simply complete a quick clinical check-in, select your next dose, and pay for it. Plus, your monthly payment remains the same regardless of your dose increasing. 

Levity also offers Mounjaro (tirzepatide), a dual action GLP-1 and GIP receptor agonist. Clinical studies show that people taking tirzepatide could lose up to 20% of their body weight. [1]

Levity vs Henry Meds

Henry Meds only offers compounded injectable medications: Compounded Liraglutide (same ingredient as Saxenda) and Compounded Semaglutide (same ingredient as Wegovy and Ozempic). Like with Levity, you pay a flat monthly fee that includes consultation and medication. However, this fee starts at $297/per month, compared to Levity’s $225/month which also includes express shipping and expert health coaching. 

You receive your Henry Meds medication every 60 days or 90 days, depending on your plan, and you have to pay an additional $100 for monthly shipments. At Levity, you only pay $225 every four weeks for a new shipment of your medication. 

Ready to try Levity? 

Start your weight loss journey with Levity. Our clinicians review your consultation and medical history to recommend the best treatment for your needs and goals. 

See if you’re eligible today.

References: 

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine [Internet]. 2022 Jun 4;387(3). Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 

Continue reading